Francisco Barrera Echegoyen
Endocrinology, Diabetes & Metabolism · Florence, SCNPI 1033643242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 245 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$618
- Xeris Pharmaceuticals, Inc.$460
- Insulet Corporation$440
- Bayer$427
- Amgen$415
- Abbott$389
- plus $3K from 23 others
Across 19 payments — averaging $311.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$6K
What the payments were for
- Food & beverage$5,48595%
- Education$2935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $618 |
| Xeris Pharmaceuticals, Inc. | 27 | $460 |
| Insulet Corporation | 16 | $440 |
| Bayer | 16 | $427 |
| Amgen(2 entities) | 14 | $415 |
| Abbott | 18 | $389 |
| Lilly USA, LLC | 17 | $308 |
| Corcept Therapeutics | 12 | $292 |
| Boehringer Ingelheim | 15 | $276 |
| BETA Bionics, Inc. | 8 | $248 |
| Sanofi-aventis U.S. LLC | 10 | $247 |
| Dexcom, Inc. | 11 | $235 |
| Medtronic | 2 | $177 |
| Intra-sana Laboratories | 8 | $156 |
| Ascensia Diabetes Care US Inc. | 7 | $144 |
| Ascendis Pharma Endocrinology Inc | 6 | $127 |
| Tandem Diabetes Care, Inc. | 6 | $126 |
| Acerus Pharmaceuticals Corporation | 1 | $125 |
| Cequr Corporation | 1 | $98 |
| AbbVie | 5 | $81 |
| Nevro Corp. | 4 | $78 |
| Novartis | 4 | $70 |
| Recordati_rare_diseases_inc. | 2 | $52 |
| Rhythm Pharmaceuticals, Inc. | 2 | $47 |
| Chiesi USA, Inc. | 2 | $41 |
| Intuity Medical Inc | 2 | $36 |
| Radius Health, Inc. | 1 | $34 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Globus Medical | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$234
- TEPEZZA$218
- MINIMED 780G$106
- Omnipod$105
- Reltone 200 Mg$103
- GLYCATE$103
- Reltone 400 Mg$103
How this compares
$5,778 in reported general payments places this provider in the 65th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 368 | $572,948 |
| OzempicSemaglutide | 378 | $522,468 |
| JardianceEmpagliflozin | 418 | $420,218 |
| TrulicityDulaglutide | 221 | $328,025 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 63 | $167,657 |
| Tresiba Flextouch U-200Insulin Degludec | 108 | $145,929 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 100 | $127,736 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $114,320 |
| Humalog Kwikpen U-200Insulin Lispro | 34 | $82,935 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 56 | $65,889 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $54,121 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $52,717 |
| Humalog Kwikpen U-100Insulin Lispro | 133 | $52,258 |
| FiaspInsulin Aspart (Niacinamide) | 22 | $47,249 |
| KerendiaFinerenone | 64 | $45,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro | $308 | $940,430722 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Fiasp, Rybelsus, Novolog | $618 | $786,954530 claims |
| Boehringer IngelheimJardiance | $276 | $420,218418 claims |
| BayerKerendia | $427 | $45,61064 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $247 | $36,72831 claims |
| Radius Health, Inc.Tymlos | $34 | $34,67113 claims |
| AbbVieSynthroid | $81 | $11,901165 claims |
| Esperion Therapeutics, Inc.Nexlizet | $18 | $5,45514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Florence
- Gerald MieleFlorence$35K
- Padigar Shyamanand TantryFlorence$6K
- Meenakshi PandeFlorence$5K
- Sonika MalikFlorence$4K
- Hany ShenoudaFlorence$3K
- Melissa Gonzalez LaraFlorence$3K
- Gauri DhirMyrtle Beach$417K
- Cory WhiteGreenville$413K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.